Global leader in the fight against diabetes Professor Andrew Boulton joins Singapore biotech CellResearch Corporation’s (“CRC”) Scientific Advisory Board.

  • Professor Andrew Boulton, Professor of Medicine, University of Manchester, UK and visiting Professor, University of Miami, FL, USA and outgoing President of the International Diabetes Federation, Past-President of the European Association for the Study of Diabetes, joins CRC SAB to facilitate and advise on the development of CorLiCyte™.
  • CorLiCyte™ is an umbilical cord lining stem cell therapy, for patients suffering with a Diabetic Foot Ulcer (“DFU”)
  • DFU is a global health emergency that will affect close to 20% of the diabetic population in their lifetime1
  • 5-year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer2

Singapore October 19, 2022: Dr Andrew Boulton joins CellResearch Corporation’s Therapeutics Scientific Advisory Board to provide strategic guidance and advance the company’s innovative scientific platform with a particular focus on the healing of chronic Diabetic Foot Ulcers.

Prof Boulton has authored more than 600 peer-reviewed manuscripts and book chapters, mainly on the diabetic lower limb and renal complications. He was a founding member of the American Diabetes Association Foot Care Interest Group and gave the launch lecture at the first meeting in Indianapolis, June 1987. He also founded the European Diabetic Foot Study Group in 1998. He is past-Editor of Diabetic Medicine and currently senior associate editor of Diabetes Care. Until December, he is President of the International Diabetes Federation; which has been leading the global diabetes federation since 1950. He is also a past-Vice-President, Programme Chair and President of the European Association for the Study of Diabetes.

“Professor Boulton is one of the foremost experts on diabetes and its concomitant complications, he has experience navigating both the US and UK healthcare systems and we are looking forward to making use of his decades of experience to further the advancement of our exciting technology” said Gavin Tan, CEO of CellResearch.

Prof Boulton added “It is a pleasure to join the Advisory Board of CellResearch Corporation. There is an urgent need for more new evidence-based therapies for diabetic foot wounds, and hopefully together with my colleagues on the Board, we will be able to advise on the optimal study design to help prove efficacy of this interesting therapy”.

Among his other distinguished roles, Prof. Boulton has been President of the European Association for the Study of Diabetes, founding Chair of the Diabetic Foot Study Group and Chair of Postgraduate Education and Hon. Secretary/ programme chair for EASD.

This news comes at an opportune moment given CRC’s completion of their Phase 1 USFDA trial to close chronic DFUs at the University of Colorado Anschutz Medical Campus under the identifier NCT04104451 in August 2022.

1 Yazdanpanah L, et al. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018;2018:7631659. Published 2018 Mar 15. doi:10.1155/2018/7631659

2 Armstrong DG, Boulton AJM, Bus S. Diabetic Foot Ulcers and their Recurrence. New England Journal of Medicine 2017: 15; 376 (24): 2367-2375.

 

About CellResearch Corporation (“CRC”)

CellResearch Corporation was founded in 2002 as a contract research provider focusing on skin cells. In 2004, the company made the discovery that the umbilical cord lining of mammals was an abundant source of both mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and holds the rights to commercialise this technology in most major markets globally. While the closure of diabetic foot ulcers is the company's first allogeneic therapy to make it to the end of Phase 1 USFDA clinical trials, CellResearchCorp has a broad therapeutic pipeline at the pre-clinical stage. Further therapies include inflammatory diseases, cardiac muscle repair, Parkinson's Disease, Age-related Macular Degeneration and Critical limb ischemia. In October, 2022 CRC has had two publications presented on the subject of diabetic foot ulcer at the prestigious DFCon Conference.

CellResearch Consumer Health Pte Ltd is a wholly owned subsidiary of CellResearchCorp and produces an innovative range of skincare and hair care products using cord lining stem cell media to power its products. It is home to two innovative brands. Calecim® Professional: Anti-aging skincare and Sollagen™: Diabetic Skincare both are powered by a proprietary ingredient: PTT-6™ a complex mixture of peptides and growth factors derived from cord lining stem cells.

CRC partner, Cordlife offers parents the opportunity to bank their child's umbilical cord tissue alongside their cord blood. Cordlife has what is believed to be the largest licensed bank of umbilical cord tissue globally. As cell therapies move into the clinic, Cordlife will have the ability to expand stem cells from a banked umbilical cord for autologous and donor-related uses.

www.cellresearchcorp.com
https://calecimprofessional.com
Business Development and Investor Relations:
Xavier Simpson T:+65 8815 6139 E: xaviersimpson@cellresearchcorp.com